Meta Platforms (NASDAQ:META) is executing a strategic reorganization of its nearly 79,000-person workforce, laying off 700 employees across Reality Labs, social media, sales, and talent acquisition.
Hyperion DeFi (NASDAQ:HYPD), the inaugural U.S. publicly traded entity dedicated to the Hyperliquid ecosystem, today reported financial results for the fourth quarter and full year ended December 31, 2025.
Novocure (NASDAQ:NVCR), a global oncology company at the forefront of cancer treatment innovation, today announced positive topline results from its Phase 2 PANOVA-4 clinical trial.
BioLineRx (NASDAQ:BLRX), a clinical-stage biopharmaceutical company focused on oncology and rare diseases, today announced the initiation of a first-in-human Phase 1/2a clinical trial evaluating GLIX1 for the treatment of recurrent and progressive glioblastoma (GBM) and other high-grade gliomas.
MeiraGTx Holdings (NASDAQ:MGTX), a vertically integrated, clinical-stage genetic medicines company, today reported financial results for the full year ended December 31, 2025, and provided a comprehensive update on its late-stage clinical pipeline.
Foresight Autonomous Holdings (NASDAQ:FRSX), an innovator in automotive vision systems, today reported financial results for the fourth quarter and full year ended December 31, 2025.
Interlink Electronics (NASDAQ:LINK), a global leader in human-machine interface and sensor technologies, today reported financial results for the fourth quarter ended December 31, 2025.
Formula Systems (NASDAQ:FORTY), a global information technology holding company, today reported record-breaking financial results for the fourth quarter and full year ended December 31, 2025.
CollPlant Biotechnologies (NASDAQ:CLGN), a regenerative and aesthetic medicine company developing innovative technologies based on its proprietary plant-derived recombinant human collagen (rhCollagen), today reported financial results for the full year ended December 31, 2025.
MetaVia (NASDAQ:MTVA), a clinical-stage biopharmaceutical company developing novel therapies for obesity and metabolic-associated steatohepatitis (MASH), today reported financial results for the full year ended December 31, 2025, and provided an update on its advancing clinical pipeline.
ParaZero Technologies (NASDAQ:PRZO), an aerospace company focused on drone safety systems for commercial and defense applications, today reported its financial results for the full year ended December 31, 2025.
OceanPal (NASDAQ:SVRN), a company historically focused on the dry bulk shipping sector, today reported its financial results for the full year ended December 31, 2025
